Precel

Quick links to important sections

Precel

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Precel

Property Description
Active ingredient Memantine hydrochloride
Form Tablets, oral solution, capsules (oral route)
Pharmacological class N-methyl-D-aspartate (NMDA) Receptor Antagonist
General purpose Support cognitive function
Origin Synthetic

What Type of Medicine is Precel?

Precel is a synthetic, prescription-only pharmaceutical preparation identified by its sole active component, Memantine hydrochloride. It is scientifically classified as an N-methyl-D-aspartate (NMDA) Receptor Antagonist. This pharmacological class defines its role as an agent that acts to modulate signals within the central nervous system. Memantine belongs to the chemical family of adamantane derivatives, which determines its specific molecular structure and method of action. Memantine is characterized as a non-competitive, low-affinity channel blocker at the NMDA receptor. This mechanism relates to the regulation of the flow of ions through nerve cell receptor channels.

Composition, Origin, and Forms

The active substance, Memantine hydrochloride, is a single-ingredient compound intended for oral administration. Precel is supplied in several dosage forms, including immediate-release film-coated tablets, as well as oral solution and extended-release capsules. The composition ensures appropriate bioavailability of the active compound, which is combined with standard pharmaceutical excipients. The molecular structure of Memantine hydrochloride is central to its pharmacological activity. The availability of different oral forms facilitates tailored administration strategies for various patient needs.

General Purpose: How Does Precel Help the Brain?

The general purpose of Precel is to support cognitive function by helping to rebalance excitatory signals in the brain. The drug works by blocking the effects of excessive glutamate, a neurotransmitter associated with overstimulation and neuronal damage—a process known as excitotoxicity. By preventing this pathological overactivation of the NMDA receptor channels, Precel aims to protect nerve cells and maintain the clarity of thought and processing, supporting overall cognitive health for patients experiencing certain neurodegenerative issues.

Regulatory References

  1. NIH: Memantine - StatPearls

What side effects are possible with Precel?

Possible Side Effects and Safety Information

The safety profile of Precel (memantine) is formally classified by government regulatory authorities based on the frequency and the physiological systems affected. Adverse reactions are grouped into categories such as Common, Uncommon, Very Rare, and Not Known, reflecting their documented incidence in clinical trials and post-marketing experience.

Official Adverse Reaction Classification

Adverse effects are documented across several System-Organ Classes (SOCs), including Nervous System Disorders (e.g., dizziness, headache, somnolence), Gastrointestinal Disorders (e.g., constipation, vomiting), and Vascular Disorders (e.g., hypertension). The most frequently reported reactions, classified as Common, include dizziness, headache, constipation, and hypertension. Reactions like confusion, fatigue, and cardiac failure are listed as Uncommon.

Serious Adverse Reactions and Safety Constraints

Certain clinically significant events are documented, such as Seizures (Very Rare) and Cardiac failure (Uncommon). Post-marketing reports also include conditions like Pancreatitis and Hepatitis (Not Known frequency). The medicine is formally contraindicated in patients with a known hypersensitivity to the active substance. Caution is recommended for use in individuals with epilepsy or a history of convulsions.

Population-Specific Safety

Specific safety considerations apply to certain patient populations. Caution is advised for those with Severe Hepatic Impairment. For patients with Severe Renal Impairment, a dose limitation to 10 mg is officially specified. Furthermore, the use of Precel is not recommended for the pediatric population or for women who are breast-feeding, reflecting the lack of established safety data for these groups.

Overdose and Emergency Response

Overdose: When to Seek Urgent Help

Overdose of Precel (Acetaminophen/Paracetamol) poses a high risk of severe, delayed liver damage (hepatotoxicity) that can be fatal. Immediate medical advice must be sought for any suspected overdose, even if the patient feels well or exhibits minimal initial symptoms.

Documented Overdose Presentations

Timeline Symptoms and Signs (as per label)
Initial (First 24 Hours) Pallor, Nausea, Vomiting, Anorexia, Abdominal pain.
Delayed (12 to 72 Hours) Onset of liver damage (which may progress), Jaundice, Right upper quadrant tenderness, Encephalopathy, Loin pain (suggesting renal damage).

Serious Outcomes and Emergency Actions

Severe poisoning can progress to acute liver failure, metabolic acidosis, renal failure with acute tubular necrosis, disseminated intravascular coagulation, haemorrhage, and death. The specific antidote, N-acetylcysteine (NAC), should be administered urgently for maximum protective effect, ideally within 8 hours of acute ingestion. Activated charcoal may be considered if the overdose was taken within one hour of presentation.

Population and Contextual Risk Factors

Patients with certain underlying conditions face an increased risk of severe toxicity, including those with chronic alcohol abuse, chronic malnutrition, dehydration, or pre-existing hepatic impairment. Overdose management for modified-release formulations is noted in regulatory documents as being complex due to unpredictable absorption and delayed peak plasma levels.

Therapeutic Uses of Precel

What Precel Treats: Main Uses and Benefits

Precel (Memantine) may be part of symptomatic management in situations where patients experience moderate-to-severe Alzheimer's disease, which is the primary condition it addresses. It is also considered relevant for easing the symptom burden in related vascular and mixed dementias. The medication is intended to assist with preserving the ability to think and remember and may help slow the loss of these core cognitive abilities.

The medication is applied in addressing symptom clusters that interfere with daily functioning and create noticeable strain. This involves managing challenging agitation, aggression, and confusion. By supporting these symptoms, Precel is intended to contribute to improved comfort during periods of heightened symptoms and assist with maintaining functional stability, providing supportive relief when symptoms interfere with routine activities.

This sustained support contributes to easing the overall symptom load during symptomatic phases and is commonly used when symptoms become more noticeable.

“The therapy is considered relevant for providing symptomatic relief and stability, and may help patients cope more steadily with symptom fluctuations during cognitive decline.”

Quick Fact: Relief for Functional and Behavioral Symptoms The therapy is relevant in clinical settings that involve conditions characterized by periods of heightened symptoms where supportive symptom management is appropriate to manage both core cognitive deficits and subsequent functional/behavioral disturbances.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Regulatory Eligibility Profile for Precel

This section outlines the population eligibility and non-eligibility rules for Precel, strictly based on information found in authoritative government regulatory documents like the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).

Classification Rule Summary (Strictly Label-Based)
Populations Contraindicated Precel must not be used by patients with a known hypersensitivity to the active substance or any of its excipients, or by patients with specific pre-existing medical conditions that are listed as absolute prohibitions in the official label.
Age-Related Rules Use is not established in pediatric populations (e.g., children under a specified age limit), as safety and efficacy data are often insufficient for these groups. Use in geriatric patients may be allowed but often requires special caution or monitoring due to potential differences in drug response or clearance.
Conditional Use / Restrictions Patients with significant organ function impairment (e.g., severe hepatic or renal dysfunction) often have restricted use status or may require mandatory dosage adjustments, as these conditions alter the drug's processing in the body.
Reproductive Status Use during pregnancy is typically not recommended or is contraindicated if risks outweigh benefits, based on documented human or animal data. Breastfeeding is generally advised to be discontinued if the drug is known to be excreted into breast milk.

What should I know about interactions with other medicines?

Precel’s official interaction profile is characterized by pharmacokinetic restrictions on elimination and key pharmacodynamic cautions regarding the central nervous system. The most significant pharmacokinetic concern involves medicines and clinical conditions that alkalinize the urine, such as Carbonic Anhydrase Inhibitors or Sodium Bicarbonate. Since Memantine’s urinary clearance is highly dependent on pH, an alkaline shift can substantially reduce its elimination, resulting in drug accumulation and increased plasma exposure. A similar accumulation risk is noted for patients with certain genitourinary conditions, including renal tubular acidosis.

A strong pharmacodynamic caution is applied to the co-administration of other NMDA receptor antagonists, including Amantadine, Ketamine, and Dextromethorphan. These compounds should be avoided due to the documented risk of additive central nervous system-related effects. The simultaneous use of Amantadine specifically carries a documented risk of pharmacotoxic psychosis.

Furthermore, substances that utilize the same renal cationic transport system for excretion (such as Cimetidine, Quinidine, and Nicotine) may compete with Memantine, which is a regulatory interaction that can also lead to elevated plasma concentrations. The official labeling also notes that the effects of L-dopa, dopaminergic agonists, and anticholinergics may be enhanced, while the effects of agents like barbiturates and neuroleptics may be modified. No mandatory timing separation rules or formal food interactions are documented.

Mechanism of Action

Selective Modulation of NMDA Receptor Signaling

Precel (Memantine) functions by regulating the glutamatergic system, the brain’s main excitatory network, to modulate chronic overexcitation. Its mechanism is centered on a precise, selective interaction with the N-methyl-D-aspartate (NMDA) receptor. The molecule is classified as a non-competitive antagonist and open-channel blocker. This interaction is inherently voltage-dependent: Memantine preferentially binds inside the channel pore when the neuron is persistently depolarized due to excessive glutamate activity. This targets the pathological signaling patterns associated with continuous activation, allowing the drug to reduce the magnitude of persistent signaling originating from overactive excitatory circuits.

Kinetic Selectivity Based on Rapid Off-Rate

This action exhibits functional selectivity based on its kinetics. Memantine has a low-to-moderate affinity, which results in rapid dissociation from the NMDA receptor channel during transient synaptic events. The kinetic profile facilitates the maintenance of transient signaling while mitigating the sustained calcium ion ( Ca^2+) influx that characterizes excitotoxic signaling. This selectivity focuses the mechanistic action on dysregulated, chronic activation.

Dosage and Administration Information

General Principles of Use

Precel (Memantine hydrochloride) is administered exclusively via the oral route and is available in formulations including immediate-release tablets, oral solution, and extended-release capsules. The protocol typically involves a dose titration period when treatment is initiated, a gradual process that involves slowly increasing the dose in weekly increments over a minimum of four weeks to reach the target maintenance level.


Dosing and Frequency Patterns

For the immediate-release form, treatment generally begins with a low dose, such as 5 mg once daily. The standard maintenance dose is 20 mg per day, which may be achieved by taking 10 mg twice daily, or as a single daily dose depending on the specific formulation. Extended-release capsules are administered once daily and are titrated to a maximum maintenance dose of 28 mg per day. Administration may occur with or without food, but maintaining a consistent daily administration time is part of the established procedural protocol.


Administration and Long-Term Course

General administration guidelines for extended-release capsules specify they must be swallowed whole. However, the entire contents of the capsule may be opened and sprinkled onto a small spoonful of applesauce and swallowed immediately, but the contents must not be chewed, crushed, or divided otherwise. For patients with severe renal impairment, the maximum daily dose is reduced to a lower level, such as 10 mg for the immediate-release form. Treatment is generally intended for long-term maintenance and is subject to regular reassessment. A single missed dose should not be doubled, and if dosing is interrupted for several days, the protocol advises resuming treatment at a lower dose and re-titrating.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Precel (Memantine)


Evidence for Use in Moderate-to-Severe Alzheimer's Disease

The primary research for Precel was studied for its use in numerous short-term, randomized, controlled clinical trials. The research examined change over time in three main areas: cognitive function, daily functional performance, and global status. Findings describe patterns of difference in cognitive and functional scores between the active treatment groups and the placebo groups. Though the magnitude of these differences is generally described as small, the research helps contextualize how patients reported their experience by tracking change over defined time intervals. Long-term effects are not fully established by these short-term controlled trials, and there is limited information for long-term outcomes such as effects on institutionalization.

Research on Behavioral and Functional Symptoms

In addition to cognitive assessments, Precel was studied for its impact on outcomes reflecting daily functioning and outcomes capturing phases of heightened symptom activity, such as managing challenging agitation, aggression, and confusion. Research explored whether the use of the medicine was associated with changes measured during the study period in the frequency and intensity of these behaviors. Findings describe patterns observed in the studies where treatment groups recorded different measurements on behavioral symptom scales compared to placebo groups.

Studies in Related Vascular and Mixed Dementias

Precel was evaluated in research contexts involving conditions beyond Alzheimer's disease, including patients diagnosed with vascular dementia and mixed dementias. Research provides insight into short-term changes in these related dementias. The evidence base for these populations is limited. In some assessments, the documented differences were mixed or the measured differences were small in magnitude.

What Research Gaps and Uncertainties Remain

Scientific reviews highlight several areas where the evidence is limited or where certainty remains low. A key point is that the overall magnitude of the difference reported on measurement scales between the active treatment and placebo is often described as small. Furthermore, comparative evidence is lacking regarding how this medicine might perform against other potential treatments in head-to-head randomized controlled trials.

Frequently Asked Questions (FAQ)

Common questions about Precel (FAQ)


Q: What specific conditions is Precel officially approved to treat?

A: According to the official prescribing information from regulatory agencies, Precel (Memantine) is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. Its purpose is to support cognitive function in patients with this specific condition.


Q: Is weight gain or weight loss a known side effect listed for Precel?

A: Official safety data indicates that unusual changes in weight, which may include either weight gain or weight loss, are reported as adverse effects. However, these are generally listed as less common or have an unknown frequency based on post-marketing experience rather than being common side effects.


Q: What kind of safety information is available regarding Precel's effect on mental health or mood?

A: Regulatory documents list several nervous system effects. Commonly reported nervous system effects include confusion and somnolence (sleepiness). Less frequently, effects such as agitation or hallucinations have been reported. In rare instances, severe psychological reactions, including psychosis (particularly if combined with certain other drugs), have been documented in safety information.


Q: Can Precel affect a person's ability to drive or operate machinery?

A: Yes. Official product information notes that Precel (Memantine) can have a minor to moderate influence on activities that require mental alertness. The underlying condition that Precel treats may also impair driving ability. Official guidance suggests that special care is necessary regarding these activities.


Q: How is the safety of Precel officially monitored by health authorities?

A: Health authorities monitor the drug's safety by collecting and reviewing reports of adverse drug reactions that occur both during controlled clinical trials and after the drug is released to the public. This continuous process, known as post-marketing surveillance, is how the safety profile is maintained and reviewed.


Q: What side effects, if experienced, should prompt a user to seek medical attention?

A: Official patient information lists several serious reactions that are documented as needing immediate medical review. These include documented serious reactions such as seizures or convulsions, signs of cardiac failure, or the onset of severe stomach pain or jaundice (yellowing of skin/eyes).


Q: What are the common signs of an interaction between Precel and other substances?

A: Drug interactions with Precel can lead to additive effects on the central nervous system (CNS). When Precel is combined with certain interacting medications, this may result in increased adverse effects like heightened confusion or hallucinations due to combined activity at the NMDA receptors.


Q: Is it known whether Precel interacts with alcohol?

A: The official product label does not typically list a formal, mandatory-warning interaction with alcohol. However, since both Precel and alcohol affect the central nervous system (CNS), there is the potential for additive central nervous system effects from both substances.


Q: Does Precel interact with over-the-counter pain relievers or cold medicines?

A: The official labeling highlights known interactions with specific compounds that may be found in over-the-counter (OTC) products. The use of Precel should be avoided with other NMDA antagonists, such as Dextromethorphan (a common cough suppressant), due to the risk of additive side effects on the nervous system.


Q: Is there an official list of major drug interactions for Precel?

A: Yes. The official product labeling, such as the Summary of Product Characteristics (SmPC) and the FDA Label, includes a formal section dedicated to drug interactions. This section details all clinically significant interactions, covering both how the body handles the drug (pharmacokinetic) and how the drug acts (pharmacodynamic) interactions.


Q: Does the medicine have any known contraindications related to heart or blood pressure issues?

A: Official labeling does not list pre-existing heart or blood pressure conditions as formal contraindications (absolute prohibitions). However, changes in blood pressure are listed as a common side effect (hypertension), and cardiac failure is an uncommon, but serious, reported adverse event.


Q: How long does it usually take for Precel to start working or for a patient to notice the expected effects?

A: Official dosing guidelines advise patients to undergo a gradual dose titration, where the amount taken is slowly increased over a period of at least three to four weeks. This procedural approach indicates that the full effect is generally established gradually as the target maintenance dose is achieved.


Q: Is Precel a drug that must be stopped gradually, or can it be stopped abruptly?

A: The official protocol advises that if dosing is interrupted for several days, re-initiation should occur at a lower dose with re-titration. This suggests that abrupt changes in treatment may require medical supervision.


Q: Is it true that Precel is a controlled substance?

A: No. In the United States, Precel (Memantine) is not listed as a scheduled drug by the Drug Enforcement Administration (DEA). However, it is an Rx-only medication, meaning it can only be obtained through a healthcare professional’s prescription.


Q: Where can a patient find the official full prescribing information or regulatory documents for Precel?

A: Official regulatory documents, such as the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC), are publicly available. Patients can often access this comprehensive documentation through their pharmacist, through government websites like DailyMed, or through reliable patient information resources provided by the regulator.

How should Precel be stored and disposed of?

The storage and disposal of Precel (Memantine hydrochloride) must strictly adhere to the conditions mandated by official regulatory labeling to ensure product quality and safety.

Storage Requirements

Condition Regulatory Rule
Temperature Store at Controlled Room Temperature (20 C to 25 C) or as specified in the product labeling.
Protection Keep the medicine in its original container and protect it from moisture and light.
Handling The product must not be frozen; keep containers tightly closed.
Stability (Liquid) The oral solution has a specific in-use shelf-life (e.g., 3 months) after first opening, after which unused medicine must be discarded.
Child Safety Keep out of the sight and reach of children as required for all prescription medications.

Disposal Instructions

Unused or expired Precel must be disposed of according to local pharmaceutical regulations. Disposal in household trash or wastewater is generally not permitted unless the product is specifically listed for such disposal by a national health authority. Utilizing a drug take-back program is the recommended method for discarding the unused product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Precel found in:

A-Z Index: